Stacy Ku
Stock Analyst at TD Cowen
(1.73)
# 3,392
Out of 5,124 analysts
6
Total ratings
50%
Success rate
1.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stacy Ku
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $45 → $60 | $49.70 | +20.72% | 1 | Oct 23, 2025 | |
| BCRX BioCryst Pharmaceuticals | Reinstates: Buy | $30 | $7.80 | +284.62% | 1 | Oct 15, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | n/a | $25.01 | - | 1 | Jan 7, 2025 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $30 | $16.15 | +85.76% | 1 | Jan 7, 2025 | |
| VRCA Verrica Pharmaceuticals | Maintains: Buy | $150 → $100 | $8.31 | +1,103.37% | 1 | Oct 21, 2024 | |
| ATXS Astria Therapeutics | Initiates: Buy | $35 | $13.09 | +167.38% | 1 | Jul 29, 2024 |
Supernus Pharmaceuticals
Oct 23, 2025
Maintains: Buy
Price Target: $45 → $60
Current: $49.70
Upside: +20.72%
BioCryst Pharmaceuticals
Oct 15, 2025
Reinstates: Buy
Price Target: $30
Current: $7.80
Upside: +284.62%
Centessa Pharmaceuticals
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $25.01
Upside: -
KalVista Pharmaceuticals
Jan 7, 2025
Initiates: Buy
Price Target: $30
Current: $16.15
Upside: +85.76%
Verrica Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $150 → $100
Current: $8.31
Upside: +1,103.37%
Astria Therapeutics
Jul 29, 2024
Initiates: Buy
Price Target: $35
Current: $13.09
Upside: +167.38%